Advertisement

Topics

Search Results for "Reminder Sample Letter Prostate Cancer"

10:51 EST 9th February 2016 | BioPortfolio

Matching Channels

Prostate Cancer in Men

Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or ...

Prostate Cancer Cellular Vaccine rDNA

Prostate specific membrane antigen PSMA

Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monit...

Abiraterone Acetate - Zytiga

On April 28, 2011, the US Food and Drug Administration (FDA) approved Zytiga (abiraterone acetate), for use in combination with prednisone for the second-line treatment of castration-resistant prost...

Prostate Mab

Matching News

GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication

GlaxoSmithKline (GSK) today announced that the Company has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the supplemental New Drug Application (sNDA) for Avo...

Extracellular Vesicles as a Fluid Biopsy for Prostate Cancer

A new review explores the potential of prostate cancer cell fragments as a diagnostic biomarker for prostate cancer. Prostate Cancer and Prostatic Diseases

Research Breakthrough Could Lead to Better Prostate Cancer Treatment

Research breakthrough could lead to better prostate cancer treatment Cancer researchers from the University of Glasgow and Royal Philips Cancer researchers have identified a gene which could help doct...

Genetics of Prostate Cancer–for health professionals (PDQ®)

SOURCE April 2015 SECTIONS Introduction Identifying Genes and Inherited Variants Associated With Prostate Cancer Risk Genes With Potential Clinical Relevance in Prostate Cancer Risk Interventions in F...

Nanoparticles hitchhike on whiteblood cells to kill tumour cells in bloodstream.

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system.  Most often, prostate cancer spreads to the bones and also to the liver or lungs. It’s rar...

Prostate Cancer: Year in Review

In 2015, the increased use of Oncotype DX prostate cancer test promoted changes in treatment received, resulting in greater recommendations and adoption of active surveillance. Also noteworthy is the ...

Bone protein inhibits prostate cancer invasion, scientists find

A secreted protein predominantly expressed in bone inhibits prostate cancer metastasis to bone, new research shows. Prostate cancer is the most frequently diagnosed cancer and the second leading cause...

Prostate cancer: Intrapatient heterogeneity in prostate cancer

A newly published study used whole-genome sequencing of multiple prostate tumour foci from several patients with intermediate-risk prostate cancer to track evolutionary patterns and delineate the mark...

Matching PubMed Articles

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial.

We previously found that inflammation in benign prostate tissue is associated with an increased odds of prostate cancer, especially higher-grade disease. Since part of this link may be due to genetics...

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Compelling and long-standing data suggest that androgens play an important role in the development of both normal prostate epithelium and prostate cancer. Although testosterone administration can indu...

MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer.

It is known that microRNAs (miRNAs) are a class of small, non-coding RNAs that act as key regulators in various physiological and pathological processes. However, the regulatory mechanisms involving m...

Significance of p53 and ki-67 expression in prostate cancer.

Prostate cancer is a major health problem throughout the developed world. Tumor grade is one of the most important prognostic factors of prostate cancer. At present, adequate prognostic markers for pr...

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer.

The management of advanced castration resistant prostate cancer (CRPC) has been rapidly changing and is still evolving. In the last years, there has been an increasing knowledge of prostate cancer bio...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement